85 results
Page 4 of 5
6-K
EX-99.2
62gt0r5b lgr
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.3
tdfic2v
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99
4fpq5q6my8ab0n0eea4
25 Jul 19
Strong clinical progress in H1, and transformative collaboration with Gilead announced
4:24pm
6-K
EX-99.2
k2fac0w
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
F-3ASR
EX-4.7
elvj5
29 Mar 19
Automatic shelf registration (foreign)
5:26pm
F-3ASR
EX-4.8
u5a xt60cd
29 Mar 19
Automatic shelf registration (foreign)
5:26pm
6-K
EX-99.2
qbw6j5l
26 Oct 18
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
4:19pm
424B5
84mozuumy4c4a4f45 wc
13 Sep 18
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
2yyr1z dft
13 Sep 18
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
12:00am
6-K
EX-99.2
w596ksk2x hgccv8
2 Aug 18
Current report (foreign)
4:03pm
6-K
EX-99.1
dkjya4yz
19 Jul 18
Current report (foreign)
6:05am
6-K
EX-99.1
y8uw5l2ilcgmn
22 May 18
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
6:00am
6-K
EX-99.1
cu9veh1kqb3f4l wr2
2 May 18
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
6:00am
6-K
EX-99.2
tkr r6j3vepzpayr2gu
27 Apr 18
Galapagos reports first quarter 2018 results
12:00am
6-K
EX-1.1
8fyp46
18 Apr 17
Galapagos announces launch of proposed public offering
12:00am
424B5
yg2qsd5af39dyhr
18 Apr 17
Prospectus supplement for primary offering
12:00am
424B5
ind xqcvdua7iow
17 Apr 17
Prospectus supplement for primary offering
12:00am